Literature DB >> 8523572

Induction of interleukin-6 after stimulation of human B-cell CD21 by Epstein-Barr virus glycoproteins gp350 and gp220.

J E Tanner1, C Alfieri, T A Chatila, F Diaz-Mitoma.   

Abstract

The cellular receptor for Epstein-Barr virus (EBV) is the type 2 complement receptor, CD21. At initial infection, EBV virion glycoproteins gp350 and gp220 bind to CD21. We report here that the cross-linking of CD21 by gp350/220 results in increased amounts of interleukin 6 (IL-6) RNA and IL-6 protein. This effect could be blocked with anti-gp350/220 and anti-CD21 monoclonal antibodies. Induction of IL-6 in B cells by EBV could be mimicked by treatment with the protein kinase C (PKC) activator phorbol 12,13-dibutyrate but not with the calcium ionophore ionomycin. IL-6 induction by EBV was inhibited with the PKC-specific inhibitor bisindolylmaleimide or the protein tyrosine kinase inhibitors methyl 2,5-dihydroxycinnamate and herbimycin A, indicating that the induction of IL-6 following CD21 cross-linking is mediated through PKC- and protein tyrosine kinase-dependent pathways.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8523572      PMCID： PMC189846     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  39 in total

1.  Impairment of natural killer functions by interleukin 6 increases lymphoblastoid cell tumorigenicity in athymic mice.

Authors:  J Tanner; G Tosato
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

2.  Use of the polymerase chain reaction in the quantitation of mdr-1 gene expression.

Authors:  L D Murphy; C E Herzog; J B Rudick; A T Fojo; S E Bates
Journal:  Biochemistry       Date:  1990-11-13       Impact factor: 3.162

3.  Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen.

Authors:  G J Hoffman; S G Lazarowitz; S D Hayward
Journal:  Proc Natl Acad Sci U S A       Date:  1980-05       Impact factor: 11.205

4.  Identification of interleukin-6 as an autocrine growth factor for Epstein-Barr virus-immortalized B cells.

Authors:  G Tosato; J Tanner; K D Jones; M Revel; S E Pike
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

5.  The tyrosine kinase lck is critically involved in the growth transformation of human B lymphocytes.

Authors:  R K Cheung; H M Dosch
Journal:  J Biol Chem       Date:  1991-05-15       Impact factor: 5.157

6.  Early events in Epstein-Barr virus infection of human B lymphocytes.

Authors:  C Alfieri; M Birkenbach; E Kieff
Journal:  Virology       Date:  1991-04       Impact factor: 3.616

7.  Regulation of B-cell growth and immunoglobulin gene transcription by interleukin-6.

Authors:  J E Tanner; G Tosato
Journal:  Blood       Date:  1992-01-15       Impact factor: 22.113

8.  The insulin-like growth factor 1 (IGF-1) receptor is responsible for mediating the effects of insulin, IGF-1, and IGF-2 in Xenopus laevis oocytes.

Authors:  M Janicot; J R Flores-Riveros; M D Lane
Journal:  J Biol Chem       Date:  1991-05-25       Impact factor: 5.157

9.  The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C.

Authors:  D Toullec; P Pianetti; H Coste; P Bellevergue; T Grand-Perret; M Ajakane; V Baudet; P Boissin; E Boursier; F Loriolle
Journal:  J Biol Chem       Date:  1991-08-25       Impact factor: 5.157

10.  Determination of the structural basis for selective binding of Epstein-Barr virus to human complement receptor type 2.

Authors:  D R Martin; A Yuryev; K R Kalli; D T Fearon; J M Ahearn
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307
View more
  15 in total

1.  Epstein-Barr virus BARF1 protein is dispensable for B-cell transformation and inhibits alpha interferon secretion from mononuclear cells.

Authors:  J I Cohen; K Lekstrom
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

Review 2.  Molecular pathways in virus-induced cytokine production.

Authors:  T H Mogensen; S R Paludan
Journal:  Microbiol Mol Biol Rev       Date:  2001-03       Impact factor: 11.056

Review 3.  Epstein-Barr virus entry.

Authors:  Lindsey M Hutt-Fletcher
Journal:  J Virol       Date:  2007-04-25       Impact factor: 5.103

Review 4.  Cell-homologous genes in the Kaposi's sarcoma-associated rhadinovirus human herpesvirus 8: determinants of its pathogenicity?

Authors:  F Neipel; J C Albrecht; B Fleckenstein
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

5.  The human cytomegalovirus UL55 (gB) and UL75 (gH) glycoprotein ligands initiate the rapid activation of Sp1 and NF-kappaB during infection.

Authors:  A D Yurochko; E S Hwang; L Rasmussen; S Keay; L Pereira; E S Huang
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

6.  Analysis of host gene expression changes reveals distinct roles for the cytoplasmic domain of the Epstein-Barr virus receptor/CD21 in B-cell maturation, activation, and initiation of virus infection.

Authors:  Mohamed S Arredouani; Manoj K Bhasin; David R Sage; Laura K Dunn; Michael B Gill; Deep Agnani; Towia A Libermann; Joyce D Fingeroth
Journal:  J Virol       Date:  2014-03-05       Impact factor: 5.103

7.  Tonsillar CD4+FOXP3+ T-regulatory cell dynamics in primary EBV infection.

Authors:  Yen-Hung Chow; Hsuen-Wen Chang; Raymond Sia; Pele Chong; Charles Sia
Journal:  Immunol Res       Date:  2011-05       Impact factor: 2.829

8.  Peptides designed to spatially depict the Epstein-Barr virus major virion glycoprotein gp350 neutralization epitope elicit antibodies that block virus-neutralizing antibody 72A1 interaction with the native gp350 molecule.

Authors:  Jerome E Tanner; Mathieu Coinçon; Valérie Leblond; Jing Hu; Janey M Fang; Jurgen Sygusch; Caroline Alfieri
Journal:  J Virol       Date:  2015-02-18       Impact factor: 5.103

Review 9.  NF-kappaB and virus infection: who controls whom.

Authors:  M Gabriella Santoro; Antonio Rossi; Carla Amici
Journal:  EMBO J       Date:  2003-06-02       Impact factor: 11.598

10.  Serum levels of interleukin 6 in recently hospitalized tick-borne encephalitis patients correlate with age, but not with disease outcome.

Authors:  M G Toporkova; S E Aleshin; S V Ozherelkov; M V Nadezhdina; J R Stephenson; A V Timofeev
Journal:  Clin Exp Immunol       Date:  2008-06       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.